Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

r, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral T
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... de 2015 BGI anunció hoy que su ... rendimiento en Hong Kong ha ... instalación de BGI en Hong Kong ... generación que recibe la certificación CAP en ... prácticas de laboratorio clínico. Junto con el exitoso proceso ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/9q4d5d/veterinary_ ) has ... Vaccines Market by Product, Diseases & Technology - Global ... The global animal vaccines market is poised to ... 2015, at a CAGR of 5.5% from 2015 to ... growing prevalence of animal diseases, increasing incidences of zoonotic ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
Breaking Medicine Technology:BGI recibe la acreditación del College of American Pathologists (CAP) 2Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
... Nycomed US Inc. today announced the appointment of Steve Andrzejewski ... US Inc., including manufacturing in Melville and Hicksville, New ... divisions Fougera, PharmaDerm and Savage Laboratories. , ... Steve Andrzejewski has been working in the ...
... 2010 Today, Novo Nordisk announced the,landmark recruitment of the 60,000th patient in ... in,the management of type 2 diabetes.[1] , , ... Spanning 28 countries across 4 continents and involving more than 3300,physicians, A1chieve(R) ... , , ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
(Date:7/2/2015)... ... 02, 2015 , ... B. E. Smith, the only full-service ... a national chief operating officer recruitment for Nicklaus Children’s Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... ... 2015 , ... Throughout the month of April, Casey’s General Stores invited customers ... Tuesday, July 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a ... a national nonprofit dedicated to restoring a sense of self, restoring the family unit, ...
(Date:7/2/2015)... ... July 02, 2015 , ... AvePoint Public Sector, Inc., a ... platforms and devices, today announced it was named the recipient of the 2015 GTRA ... award, given out by the Government Technology Research Alliance (GTRA), was presented June 29 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it has made two key appointments at ... General Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid ...
Breaking Medicine News(10 mins):Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... Arizona State University has used molecular biology tricks to create ... the ones that occurred naturally. ,John ... proteins in a fraction of the three billion years it ... to some surprisingly new lessons on how to optimize proteins ...
... University of Nottingham experts have joined forces with Canadian ... weapons in the fight against food poisoning . ... to develop methods for the control of Campylobacter ... England and Wales, according to the Health Protection Agency. ...
... a child is a uniquely enjoyable process. Why spoil it ... midwives, ask freebirthers . ,Delivering their own babies ... "fearmongering" by doctors and midwives and confidently catch their own ... uses the same hormones as lovemaking - so why would ...
... expectant mothers who smoke during pregnancy may be exposing ... disorder (ADHD), according to a study published in the ... prenatal exposure to smoking in the mothers womb puts ... ,During the course of study, the ...
... years ago, retail pioneer and philanthropist A. Alfred Taubman lost ... fatal disease thats better known as Lou Gehrigs disease or ... Sen. Jacob Javits slowly succumb to the nerve-killing condition has ... him to support ALS research at the University of Michigan ...
... seeking to prosecute director Michael Moore for taking volunteers on ... admission from New Yorks civic authorities. ,City's chief ... from the twin towers contributed to the death of Felicia ... Sept. 11 as she ran from her office a block ...
Cached Medicine News:Health News:Experts to Develop New Weapons Against Food Poisoning 2Health News:Experts to Develop New Weapons Against Food Poisoning 3Health News:Delivering Baby, the Natural Way. 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 3Health News:Death from Exposure to WTC Dust Confirmed 2
... hydrophilic acrylic IOL is the newest advance ... with the patient and surgeon in mind. ... optic polymerically crosslinked with PMMA haptics to ... excellent visual performance and biocompatibility. The high ...
... : the 1st monobloc hard ... an exclusive and patented process ... designed the first single piece ... the FZ60. This technology warrantes ...
TRIPODE Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
Medicine Products: